- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Construction and application of anticoagulant pharmacy service model based on the integrated theory of health behavior change
- ZHONGGUO YAOFANG Vol. 35, Issue 23, Pages: 2948-2953(2024)
- 作者机构：
1.石河子大学药学院，新疆 石河子 832003
2.石河子大学第一附属医院药学部，新疆 石河子 832000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.23.18
CLC： R973+.2Published：15 December 2024，
Received：15 August 2024，
Revised：13 November 2024，
- 稿件说明：
移动端阅览
梁侠兵,凡保华,文志萍等.基于健康行为改变整合理论的抗凝药学服务模式构建与应用 Δ[J].中国药房,2024,35(23):2948-2953.
LIANG Xiabing,FAN Baohua,WEN Zhiping,et al.Construction and application of anticoagulant pharmacy service model based on the integrated theory of health behavior change[J].ZHONGGUO YAOFANG,2024,35(23):2948-2953.
梁侠兵,凡保华,文志萍等.基于健康行为改变整合理论的抗凝药学服务模式构建与应用 Δ[J].中国药房,2024,35(23):2948-2953. DOI： 10.6039/j.issn.1001-0408.2024.23.18.
LIANG Xiabing,FAN Baohua,WEN Zhiping,et al.Construction and application of anticoagulant pharmacy service model based on the integrated theory of health behavior change[J].ZHONGGUO YAOFANG,2024,35(23):2948-2953. DOI： 10.6039/j.issn.1001-0408.2024.23.18.
摘要
目的
2
建立药师主导的基于健康行为改变整合理论（ITHBC）的抗凝药学服务模式，并分析其应用效果。
方法
2
参考相关文献，并征求药学部、呼吸科、血管外科等科室共8名多学科专家意见，最终形成药师主导的基于ITHBC的抗凝药学服务模式。选择2023年12月－2024年6月石河子大学第一附属医院的VTE住院患者为研究对象，采用随机数字表法将其分为干预组（58例）和对照组（60例）。干预组采取药师主导的基于ITHBC的抗凝药学服务模式，对照组采取常规抗凝药学服务模式。比较两组患者启动抗凝治疗3个月时的抗凝达标率、药物不良反应发生率、用药依从性评分、抗凝药物处方依从率，并进行经济学评价。
结果
2
在启动抗凝治疗3个月时，干预组患者抗凝达标率、用药依从性评分、抗凝药物处方依从率均显著高于对照组（
P
＜0.05）。两组患者的药物不良反应总发生率差异无统计学意义（
P
＞0.05）。每增加1%的抗凝达标率，医院需多投入的药师服务费用为4.35元。与2023年我国人均国内生产总值（GDP，89 358元）相比，增加50%抗凝达标率的增量成本-效果比值远低于1倍人均GDP。
结论
2
药师主导的基于ITHBC的抗凝药学服务模式可有效改善VTE患者抗凝治疗结局，提升患者用药依从性，提高患者对抗凝药物不良反应的认识和识别能力，具有一定的经济和社会效益。
Abstract
OBJECTIVE
2
To establish anticoagulation pharmaceutical service model based on the integrated theory of health behavior change （ITHBC）， and analyze its effects.
METHODS
2
Referring to relevant literature and soliciting opinions from 8 experts from departments such as pharmacy， respiratory medicine， and vascular surgery， a anticoagulation pharmaceutical service model based on ITHBC was ultimately formed. VTE inpatients were selected from The First Affiliated Hospital of Shihezi University from December 2023 to June 2024 as the research subjects. They were randomly assigned into intervention group （58 cases） and control group （60 cases） using a random number table method. The intervention group implemented pharmacist-led anticoagulant pharmaceutical service model based on ITHBC， while the control group adopted a conventional anticoagulant pharmaceutical service model. The anticoagulation-related outcomes of two groups were compared after 3 months： anticoagulation compliance rate， the incidence of adverse drug reactions， the score of medication adherence and compliance rate of anticoagulant prescription； economic evaluation was conducted.
RESULTS
2
After implementing ITHBC-based anticoagulant pharmaceutical services for 3 months， the intervention group had higher anticoagulation compliance rate， score of medication adherence， and compliance rate of anticoagulant prescription than the control group （
P
＜0.05）. There was no statistically significant difference in the total incidence of adverse drug reactions between the two groups （
P
＞0.05）. For every 1% point increase in anticoagulant compliance rate， the hospital needed to invest 4.35 yuan additionally in anticoagulant pharmaceutical service fees. Compared with China’s per capita gross domestic product （GDP， 89 358 yuan） in 2023， the incremental cost-effectiveness ratio value that increased the anticoagulation compliance rate by 50% is far less than one time of per capita GDP.
CONCLUSIONS
2
The pharmacist-led anticoagulant pharmaceutical service model based on ITHBC can effectively improve the outcomes of anticoagulant therapy for VTE patients， enhance medication compliance， improve patients’ awareness and recognition of adverse drug reactions to anticoagulants， and has certain economic and social benefits.
关键词
健康行为改变整合理论静脉血栓栓塞症抗凝治疗药学服务用药依从性
Keywords
venous thromboembolismanticoagulant therapypharmaceutical caremedication compliance
references
ORTEL T L，NEUMANN I，AGENO W，et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism：treatment of deep vein thrombosis and pulmonary embolism[J]. Blood Adv，2020，4（19）：4693-4738.
《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志，2018，98（36）：2861-2888.
Expert Committee of Guidelines for Prevention and Treatment of Thrombotic Diseases in China. Guidelines for prevention and treatment of thrombotic diseases in China[J]. Natl Med J China，2018，98（36）：2861-2888.
中华医学会呼吸病学分会肺栓塞与肺血管病学组，中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会，全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志，2018，98（14）：1060-1087.
Pulmonary Embolism and Pulmonary Vascular Disease Group of Respiratory Disease Branch of Chinese Medical Association，Pulmonary Embolism and Pulmonary Vascular Disease Working Committee of Respiratory Medicine Branch of Chinese Medical Doctor Association，National Pulmonary Embolism and Pulmonary Vascular Disease Prevention and Treatment Collaboration Group. Guidelines for diagnosis，treatment and prevention of pulmonary thromboembolism[J]. Natl Med J China，2018，98（14）：1060-1087.
曹慧康，连介琼. 郑州市某三甲医院肿瘤患者抗凝药物使用状况及不良反应监测[J]. 感染、炎症、修复，2022，23（4）：221-225.
CAO H K，LIAN J Q. Anticoagulant drugs use status and adverse reactions monitoring in tumor patients in a tertiary hospital of Zhengzhou[J].Infect Inflamm Rep，2022，23（4）：221-225.
植艳茹，闫雪利，李海燕，等. 静脉血栓栓塞症患者出院后抗凝治疗依从性现状及其影响因素[J]. 解放军护理杂志，2022，39（5）：31-34.
ZHI Y R，YAN X L，LI H Y，et al. Anticoagulation therapy adherence among patients with venous throm- boembolism in post-discharge and its influencing factors[J]. Nurs J Chin PLA，2022，39（5）：31-34.
接恒博. 抗凝药物管理可行性研究与医院药学实践[D]. 北京：北京协和医学院，2022.
JIE H B. Feasibility study on anticoagulant drug management and hospital pharmacy practice[D].Beijing：Peking Union Medical College，2022.
RYAN P. Integrated theory of health behavior change：background and intervention development[J]. Clin Nurse Spec，2009，23（3）：161-170.
BAO Y H，WANG C X，XU H P，et al. Effects of an mHealth intervention for pulmonary tuberculosis self-management based on the integrated theory of health behavior change：randomized controlled trial[J]. JMIR Public Health Surveill，2022，8（7）：e34277.
胡哲，雷丹丹，赵益，等. 基于健康行为改变整合理论的护理干预对糖尿病视网膜病变患者的影响[J]. 中华护理杂志，2024，59（3）：300-307.
HU Z，LEI D D，ZHAO Y，et al. The effect of nursing intervention based on the integrated theory of health beha- vior change on the health behavior of patients with diabetes retinopathy[J]. Chin J Nurs，2024，59（3）：300-307.
中华医学会外科学分会血管外科学组. 深静脉血栓形成的诊断和治疗指南：第3版[J]. 中国普通外科杂志，2017，32（9）：807-812.
Vascular Surgery Group of the Surgery Branch of the Chinese Medical Association. Guidelines for diagnosis and treatment of deep venous thrombosis：third edition[J]. Chin J Gen Surg，2017，32（9）：807-812.
重庆市医院协会药事管理专业委员会，钱妍，赵春景. 抗凝药物审方规则专家共识[J]. 中国药房，2023，34（24）：2951-2967.
Pharmaceutical Administration Committee of Chongqing Hospital Association，QIAN Y，ZHAO C J. Expert consensus on prescription review rules of anticoagulants[J]. China Pharm，2023，34（24）：2951-2967.
中国心胸血管麻醉学会心血管药学分会抗凝药师专科协作组，郑英丽. 直接口服抗凝药合理用药和处方质量评价药学建议[J]. 中国循环杂志，2024，39（3）：217-227.
Anticoagulation-cardiovascular Pharmacists Collaboration Group，Professional Committee of Cardiovascular Pharmacy，Chinese Society of Cardiothoracic and Vascular Anesthesiology，ZHENG Y L. Pharmaceutical recommendation on rational use and the prescription quality evaluation of direct oral anticoagulants[J]. Chin Circ J，2024，39（3）：217-227.
何瑛，柳萌，郭淑芸，等. 延续护理对下肢深静脉血栓形成患者抗凝治疗依从性的影响[J]. 中华现代护理杂志，2017，23（22）：2869-2872.
HE Y，LIU M，GUO S Y，et al. Effects of extended care on compliance of anticoagulant therapy in patients with lower limb deep venous thrombosis[J]. Chin J Mod Nurs，2017，23（22）：2869-2872.
WANG X F，JI X G. Sample size estimation in clinical research：from randomized controlled trials to observational studies[J]. Chest，2020，158（Suppl. 1）：S12-S20.
潘龙飞，孟燕，牛泽群，等. 低分子肝素序贯利伐沙班与华法林治疗急性肺栓塞的短期疗效比较研究[J]. 实用心脑肺血管病杂志，2020，28（10）：25-31.
PAN L F，MENG Y，NIU Z Q，et al. Comparative study on short-term efficacy of low molecular weight heparin sequential rivaroxaban and warfarin in the treatment of acute pulmonary embolism[J]. Pract J Card Cereb Pneumal Vasc Dis，2020，28（10）：25-31.
侯玉芬，刘政. 下肢深静脉血栓形成诊断及疗效标准：2015年修订稿[J]. 中国中西医结合外科杂志，2016，22（5）：520-521.
HOU Y F，LIU Z. Diagnostic and therapeutic criteria for deep venous thrombosis of lower extremities：revised edition 2015[J]. Chin J Surg Integr Tradit West Med，2016，22（5）：520-521.
CHAN A H Y，HORNE R，HANKINS M，et al. The medication adherence report scale：a measurement tool for elici-ting patients’ reports of nonadherence[J]. Br J Clin Pharmacol，2020，86（7）：1281-1288.
肖桂荣，章琦蕴芮，唐光敏，等.万古霉素治疗药物监测药学服务模式构建及效果与经济性评价[J]. 中国药师，2021，24（3）：499-504.
XIAO G R，ZHANG Q Y R，TANG G M，et al. Establishment of a pharmaceutical care mode for therapeutic drug monitoring of vancomycin and evaluation of its effectiveness and economics[J]. China Pharmacist，2021，24（3）：499-504.
ZHANG H X，LI X，HUO H Q，et al. Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital[J]. PLoS One，2014，9（2）：e88971.
温泽淮，李玲，刘艳梅，等.实效性随机对照试验的技术规范[J].中国循证医学杂志，2019，19（7）：794-802.
WEN Z H，LI L，LIU Y M，et al. Technical guidance for pragmatic randomized controlled trials[J]. Chin J Evid-based Med，2019，19（7）：794-802.
曹敬元，张媛媛，王立丹，等. 利伐沙班致亚洲患者出血危险因素Meta分析[J]. 中国药业，2024，33（10）：118-123.
CAO J Y，ZHANG Y Y，WANG L D，et al. Risk factors of bleeding induced by rivaroxaban in Asian patients：a meta-analysis[J]. China Pharm，2024，33（10）：118-123.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.